Genscript Biotech Corporation, an investment holding company, engages in the manufacture and sale of life science research products and services in the United States of America, Europe, Mainland China, Europe, Asia Pacific, and internationally. It operates through Life Science Services and Products; Biologics Development Services; and Industrial Synthetic Biology Products segments. The Life Science Services and Products segment provide research services and products which are used in fundamental to life-science research and application. The Biologics Development Services segment which helps biopharmaceutical and biotech companies accelerate the development of therapeutic antibodies, and gene/cell therapy products with an integrated platform. The Industrial Synthetic Biology Products segment develops and produces industrial enzymes through non-pathogenic microbial strains constructed using genetic engineering. It also offers SurePAGE, a precast gel series; CytoSinct, a Nanobeads product and services; and Benz-Neburase, a genetically engineered endonuclease. In addition, the company provides automated protein and antibody purification system; automated maxi-plasmid purification; automated mini-scale purification for plasmid, protein, and antibody; eBlot and eStain, a protein transfer and staining system; eZwest Lite, an automated western blotting device; CytoSinct, a cell isolation solution; pharmacokinetics and immunogenicity ELISA kits; COVID-19 detection cPass technology kits; and GenBox, a mini electrophoresis tank. It serves antibody drug discovery; gene therapy; vaccine; in vitro diagnostics; gene editing; plant biology; and synthetic biology solutions. The company was founded in 2002 and is headquartered in Wan Chai, Hong Kong.
Frequently asked questions
What sector does Genscript Biotech Corp (1548) operate in?
Genscript Biotech Corp belongs to the Healthcare sector and operates in the Biotechnology industry.
What is Genscript Biotech Corp (1548) current stock price?
As of the latest data, Genscript Biotech Corp stock price is HK$39.06, with a previous close of HK$37.22. Genscript Biotech Corp gained HK$1.84 in the last trading session, representing a 4.94% increase.
What is Genscript Biotech Corp (1548) current market capitalization?
Genscript Biotech Corp market cap is approximately 85.86 billion.
What is Genscript Biotech Corp (1548) EBITDA?
Genscript Biotech Corp EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is 89.76 million.
Does Genscript Biotech Corp (1548) pay dividends?
No. Genscript Biotech Corp does not pay a dividend.
When is Genscript Biotech Corp (1548) next earnings report?
Genscript Biotech Corp is expected to release its next earnings report on June 30, 2026.
What is Genscript Biotech Corp (1548) beta (volatility) score?
Genscript Biotech Corp has a beta of 0.979, meaning its volatility is roughly in line with the market.
